The CJC-1295 research record

2005: selecting the long-acting compound

The CJC-1295 story begins with a duration problem. A natural hormone signal is brief; the designers wanted a GHRH analog that would survive longer. In Jette and colleagues’ rat and in vitro work, the lead combined stabilising substitutions with a chemical handle that bound circulating albumin.

In rats, growth-hormone exposure over 2 hours was 4-fold greater than with unconjugated hGRF(1-29). The peptide remained detectable beyond 72 hours. The laboratory work also examined resistance to DPP-IV, an enzyme that breaks down the natural peptide.

The engineering paper earns my admiration through its specificity: a clearly stated problem and an observable solution. Its subjects were rats and laboratory preparations. The later claims about human recovery still needed experiments of their own.

2006: Teichman’s volunteer study

Teichman and colleagues studied healthy adults aged 21-61. Single subcutaneous doses of 30 or 60 micrograms/kg produced dose-dependent increases in growth hormone and IGF-1. Subcutaneous means under the skin; these figures describe the experiment.

Mean growth hormone rose 2- to 10-fold for 6 days or more. IGF-1 rose 1.5- to 3-fold for 9-11 days, and after multiple doses stayed above baseline up to 28 days. The estimated CJC-1295 half-life was 5.8-8.1 days.

The result answers whether the long-acting design can sustain hormone release in people. Sleep quality, strength, recovery and long-term health remained separate questions. The timing page separates the measurements that so often get compressed into a single duration.

2006: Ionescu and Frohman

Ionescu and Frohman studied healthy men aged 20-40 after a single dose of 60 or 90 micrograms/kg. One week later, basal growth hormone—the level between pulses—was approximately 7.5-fold higher. Mean growth hormone was about 46% higher and IGF-1 about 45% higher. Pulse frequency and magnitude were unaltered.

I had expected “long-acting” to imply a flattened rhythm. This paper corrected that expectation: the background level rose while the pulses persisted. That is a more interesting result than the vague description “more natural,” which adds a judgment the experiment did not test.

2006: growth in GHRH-knockout mice

Alba and colleagues’ mice could not make GHRH. CJC-1295 restored normal weight and length when the mice received 2 micrograms every 24 hours; longer gaps of 48-72 hours were progressively less effective. Pituitary GH mRNA also increased.

This is a growth-restoration experiment in a genetically altered mouse. Its appeal is easy to understand, but its setting is unusually specific. The dosage record preserves that setting beside the amount rather than letting a mouse schedule drift into human instructions.

2009: proteins in human serum

In Sackmann-Sala and colleagues’ study of 11 healthy young men, CJC-1295 changed the serum protein profile. Apolipoprotein A1 and a transthyretin isoform decreased; an albumin fragment and immunoglobulin/beta-hemoglobin species increased. Some of the signals correlated with IGF-1.

The authors were identifying candidate biomarkers of GH/IGF-1 activation. The proteomics paper broadens the response beyond an isolated laboratory value: several proteins changed. It still leaves the clinical value of those changes to be established.

The discontinued Phase 2 programme

The registered trial NCT00267527 concerned HIV-associated visceral obesity, meaning excess fat around internal organs in people with HIV. The long-acting DAC programme was discontinued before approval.

A patient death during the development era is frequently cited in accounts of the halt. The public record has not established that CJC-1295 caused it. Treating the death as a proven indictment troubles me, as does treating the uncertainty as a clean bill of health. The defensible conclusion is narrower: the programme stopped, and the later clinical evidence is missing.

2010: analytical identification

Henninge and colleagues identified CJC-1295 in an unknown pharmaceutical preparation using high-resolution LC-MS/MS, a technique that separates compounds and examines their molecular fragments.

That is an odd afterlife for a molecule with an unfinished therapeutic programme: its identity could be established analytically while its health benefits remained unsettled. The study identified the material examined; it supplied no clinical efficacy result.

CJC-1295 ipamorelin and related analogs

CJC-1295 and ipamorelin stimulate growth-hormone release through different receptors. That gives the pairing a biological rationale, but controlled efficacy data for this specific combination in healthy adults are lacking. The 2025 GHRH-analog review provides the wider pharmacological context.

A retrospective study in men receiving testosterone therapy is sometimes relevant to the wider secretagogue discussion. Its regimen contained GHRP-6 plus GHRP-2 plus sermorelin; it contained neither CJC-1295 nor ipamorelin. The ingredients are my objection: this result concerns a different combination.

For searches about CJC-1295 vs sermorelin, the useful comparison concerns chemical design, duration and each compound's own clinical record. Tesamorelin has FDA approval for HIV-associated abnormal fat accumulation; CJC-1295 has no human-use approval. The review of the analog class discusses these different therapeutic and investigational positions.